07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

Xigris drotrecogin alfa: Additional Phase III data

Additional data from the double-blind, international Phase III PROWESS-SHOCK trial in 1,697 patients showed that Xigris led to a 90-day mortality rate of 34.1% vs. 32.7% for placebo (p=0.56). In a subgroup of patients with...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Clinical News

Xigris drotrecogin alfa: Development discontinued

Eli Lilly withdrew Xigris from the global market after data from the double-blind, international Phase III PROWESS-SHOCK trial in 1,696 patients showed that the sepsis drug missed the primary endpoint of significantly reducing the 28-day...
00:39 , Oct 26, 2011 |  BC Extra  |  Top Story

Lilly pulls Xigris worldwide

Eli Lilly and Co. (NYSE:LLY) withdrew Xigris drotrecogin alfa from the global market after the sepsis drug missed the primary endpoint of significantly reducing the 28-day all-cause mortality rate vs. placebo in the postmarketing Phase...
07:00 , Sep 5, 2011 |  BioCentury  |  Strategy

Back to School: Innovation & collaboration

Since the economic downturn of 2008, doom has become ingrained in the biopharma narrative. According to the mantra, budgets for great science have flatlined. New startups can't find VC money to translate great science because...
07:00 , Jun 13, 2011 |  BioCentury  |  Product Development

Spinout's gamble on Xigris

Eli Lilly and Co. spinout BioCritica Inc. and its investors are betting that new data on sepsis drug Xigris drotrecogin alfa can increase the drug's use, reversing a negative sales trend. Lilly, NovaQuest Capital and...
07:00 , May 30, 2011 |  BC Week In Review  |  Company News

BioCritica, Eli Lilly deal

Eli Lilly formed newco BioCritica with investors Care Capital and NovaQuest. BioCritica will have exclusive rights in the U.S. to develop and commercialize Lilly's sepsis drug Xigris drotrecogin alfa and will have options to license...
23:25 , May 23, 2011 |  BC Extra  |  Company News

Lilly forms newco

Eli Lilly and Co. (NYSE:LLY) formed newco BioCritica Inc. (Indianapolis, Ind.) with investors Care Capital and NovaQuest. BioCritica will have exclusive rights in the U.S. to develop and commercialize Lilly's sepsis drug Xigris drotrecogin alfa...